| 前收市價 | 9.52 |
| 開市 | 9.52 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 9.52 - 9.52 |
| 52 週波幅 | 9.13 - 17.00 |
| 成交量 | |
| 平均成交量 | 2,406 |
| 市值 | 18.25B |
| Beta 值 (5 年，每月) | 0.29 |
| 市盈率 (最近 12 個月) | 476.05 |
| 每股盈利 (最近 12 個月) | 0.02 |
| 業績公佈日 | 2024年7月30日 - 2024年8月05日 |
| 遠期股息及收益率 | 0.48 (5.01%) |
| 除息日 | 2024年9月30日 |
| 1 年預測目標價 | 無 |
Yahoo FinanceBiden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations
The Biden administration revealed the first 10 drugs that will face the Medicare negotiation process under the Inflation Reduction Act.
Yahoo FinanceMedicare drug price negotiations unlikely to be derailed by lawsuits: UBS
UBS believes there is little chance the lawsuits brought on by pharma companies will delay Medicare pricing negotiations.
BenzingaAstellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as X-linked myotubular myopathy (XLMTM). Preclinical gene therapy candidate KT430 will seek to address XLMTM, a rare and life-threatening neuromuscular disease leading to severe muscle weakness, affecting predominantly males, with an incidence rate of approximately 1 in 40,000-50,000 newborn boys globally. The move comes after four deaths and
